Pub Date : 2025-12-18DOI: 10.1001/jamaophthalmol.2025.4196
Eleni Papageorgiou, Ioanna Grivea, Sofia Androudi
This case report discusses a diagnosis of optic nerve colobomatous cyst diagnosed in an infant who presented with left exotropia and no accompanying systemic abnormalities.
本病例报告讨论了视神经结肠囊肿的诊断，诊断在一个婴儿谁提出了左外斜视，并没有伴随全身异常。
{"title":"Optic Nerve Colobomatous Cyst in an Infant","authors":"Eleni Papageorgiou, Ioanna Grivea, Sofia Androudi","doi":"10.1001/jamaophthalmol.2025.4196","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2025.4196","url":null,"abstract":"This case report discusses a diagnosis of optic nerve colobomatous cyst diagnosed in an infant who presented with left exotropia and no accompanying systemic abnormalities.","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"21 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145801032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-18DOI: 10.1001/jamaophthalmol.2025.4174
Jinhua Liu, Honglei Liu
This case report discusses a diagnosis of mucosa-associated lymphoid tissue (MALT) in a patient in their 60s with a 17-year history of a left eyelid and periorbital mass.
{"title":"Treatment of Orbital MALT With Local and Systemic Rituximab","authors":"Jinhua Liu, Honglei Liu","doi":"10.1001/jamaophthalmol.2025.4174","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2025.4174","url":null,"abstract":"This case report discusses a diagnosis of mucosa-associated lymphoid tissue (MALT) in a patient in their 60s with a 17-year history of a left eyelid and periorbital mass.","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"27 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145801026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-18DOI: 10.1001/jamaophthalmol.2025.3642
Elaine Botros, Hyun Sue Kim, Kimberly E. Stepien
This case report discusses presumed progression of maculopathy secondary to pentosan polysulfate sodium prescribed for daily use over a period of 4 years in a patient with a history of interstitial cystitis.
本病例报告讨论了一名有间质性膀胱炎病史的患者，每日服用戊聚糖聚硫酸钠后继发黄斑病变的推定进展。
{"title":"Progression of Presumed Pentosan Polysulfate Sodium Maculopathy After Drug Cessation","authors":"Elaine Botros, Hyun Sue Kim, Kimberly E. Stepien","doi":"10.1001/jamaophthalmol.2025.3642","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2025.3642","url":null,"abstract":"This case report discusses presumed progression of maculopathy secondary to pentosan polysulfate sodium prescribed for daily use over a period of 4 years in a patient with a history of interstitial cystitis.","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"46 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145801024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.1001/jamaophthalmol.2025.5057
Shu Xu, Philippa Clarke, Michelle J. Sun, Joshua R. Ehrlich
Importance Older adults with poor vision are more likely to fall. However, there has been little research to understand whether this association is concentrated among individuals with specific exposures, such as home environmental hazards. Objective To assess the association between differences in visual function, home environmental hazards, and falls. Design, Setting, and Participants This population-based cross-sectional study used data from the National Health and Aging Trends Study, which gathers nationally representative data on Medicare beneficiaries aged 65 years and older in the US. A total of 4648 community-dwelling older adults who completed visual function tests and the home environment instrument in 2022 were included. Data were analyzed from September 2024 to March 2025. Exposure Objective measured visual function was assessed using binocular presenting distance visual acuity (DVA; logMAR) and contrast sensitivity (CS: logCS). Home hazards included absence of grab bars in the bathroom, tripping hazards, and broken flooring, as well as an ordinal variable representing cumulative hazards (0, 1, ≥2). Main Outcomes and Measures Falls were defined as any self-reported fall in the past month. Survey-weighted multivariable logistic regression assessed the associations of visual function, home hazards, and falls. Results The survey-weighted prevalence of home hazards among 4648 participants (53.6% female) was 47.0% (no grab bars), 9.5% (tripping hazards), 4.5% (broken flooring), and 7.3% (≥2 hazards). Mean (SD) DVA was 0.10 (0.18) logMAR and mean (SD) CS was 1.72 (0.23) logCS. Worse DVA and CS were associated with falling in homes with hazards, including no grab bars (DVA: OR, 1.14; 95% CI, 1.02-1.27; CS: OR, 0.91; 95% CI, 0.84-1.00), tripping hazards (DVA: OR, 1.29; 95% CI, 1.11-1.49; CS: OR, 0.87; 95% CI, 0.78-0.98), and broken flooring (DVA: OR, 1.47; 95% CI, 1.26-1.70; CS: OR, 0.79; 95% CI, 0.68-0.93). The presence of multiple hazards further strengthened this association (DVA: OR, 1.31; 95% CI, 1.12-1.53; CS: OR, 0.93; 95% CI, 0.86-1.00). Conclusions and Relevance The association between differences in visual function and falls among older adults in this study was shaped by the home environment. These findings underscore the potential importance of considering both intrinsic and extrinsic risk factors in fall prevention and highlight the potential for targeted strategies that include home safety interventions for individuals with poor visual function.
{"title":"The Role of Home Hazards in the Association Between Visual Function and Falls in Older Adults","authors":"Shu Xu, Philippa Clarke, Michelle J. Sun, Joshua R. Ehrlich","doi":"10.1001/jamaophthalmol.2025.5057","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2025.5057","url":null,"abstract":"Importance Older adults with poor vision are more likely to fall. However, there has been little research to understand whether this association is concentrated among individuals with specific exposures, such as home environmental hazards. Objective To assess the association between differences in visual function, home environmental hazards, and falls. Design, Setting, and Participants This population-based cross-sectional study used data from the National Health and Aging Trends Study, which gathers nationally representative data on Medicare beneficiaries aged 65 years and older in the US. A total of 4648 community-dwelling older adults who completed visual function tests and the home environment instrument in 2022 were included. Data were analyzed from September 2024 to March 2025. Exposure Objective measured visual function was assessed using binocular presenting distance visual acuity (DVA; logMAR) and contrast sensitivity (CS: logCS). Home hazards included absence of grab bars in the bathroom, tripping hazards, and broken flooring, as well as an ordinal variable representing cumulative hazards (0, 1, ≥2). Main Outcomes and Measures Falls were defined as any self-reported fall in the past month. Survey-weighted multivariable logistic regression assessed the associations of visual function, home hazards, and falls. Results The survey-weighted prevalence of home hazards among 4648 participants (53.6% female) was 47.0% (no grab bars), 9.5% (tripping hazards), 4.5% (broken flooring), and 7.3% (≥2 hazards). Mean (SD) DVA was 0.10 (0.18) logMAR and mean (SD) CS was 1.72 (0.23) logCS. Worse DVA and CS were associated with falling in homes with hazards, including no grab bars (DVA: OR, 1.14; 95% CI, 1.02-1.27; CS: OR, 0.91; 95% CI, 0.84-1.00), tripping hazards (DVA: OR, 1.29; 95% CI, 1.11-1.49; CS: OR, 0.87; 95% CI, 0.78-0.98), and broken flooring (DVA: OR, 1.47; 95% CI, 1.26-1.70; CS: OR, 0.79; 95% CI, 0.68-0.93). The presence of multiple hazards further strengthened this association (DVA: OR, 1.31; 95% CI, 1.12-1.53; CS: OR, 0.93; 95% CI, 0.86-1.00). Conclusions and Relevance The association between differences in visual function and falls among older adults in this study was shaped by the home environment. These findings underscore the potential importance of considering both intrinsic and extrinsic risk factors in fall prevention and highlight the potential for targeted strategies that include home safety interventions for individuals with poor visual function.","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"4 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145717999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.1001/jamaophthalmol.2025.5071
Alexander T Hong,Forest Lin,Ivan Y Luu,Jay M Stewart,Jeremy D Keenan
{"title":"Prescribing Patterns of First-Line Therapy for Bacterial Keratitis.","authors":"Alexander T Hong,Forest Lin,Ivan Y Luu,Jay M Stewart,Jeremy D Keenan","doi":"10.1001/jamaophthalmol.2025.5071","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2025.5071","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"38 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145718000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.1001/jamaophthalmol.2025.5068
Warren W Pan,Ian Waters,Jonah Yousif,Zachery R Reichert,Mark W Johnson,Jason Miller,K Thiran Jayasundera
{"title":"Acute and Substantial Vision Loss After Pembrolizumab Immunotherapy for Bladder Cancer.","authors":"Warren W Pan,Ian Waters,Jonah Yousif,Zachery R Reichert,Mark W Johnson,Jason Miller,K Thiran Jayasundera","doi":"10.1001/jamaophthalmol.2025.5068","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2025.5068","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"6 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145718001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.1001/jamaophthalmol.2025.5078
Gabriella De Salvo, Peter M. Maloca
This case report discusses a diagnosis of epiretinal hyperproliferative complex in a male patient aged 75 years with a history of multiple myeloma who reported blurred vision in his left eye persisting after cataract surgery.
本病例报告讨论一名75岁男性患者，有多发性骨髓瘤病史，白内障手术后左眼视力持续模糊。
{"title":"Epiretinal Hyperproliferative Complex","authors":"Gabriella De Salvo, Peter M. Maloca","doi":"10.1001/jamaophthalmol.2025.5078","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2025.5078","url":null,"abstract":"This case report discusses a diagnosis of epiretinal hyperproliferative complex in a male patient aged 75 years with a history of multiple myeloma who reported blurred vision in his left eye persisting after cataract surgery.","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"15 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145718239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.1001/jamaophthalmol.2025.5069
Adrian T. Fung, David Sarraf, Jose M. Carrillo, Alessandro Feo, Shahin Faghihi, Caroline M. Borie, Liam Lim, Alex P. Hunyor, Nicolas A. Yannuzzi
Importance Retinal toxic effects due to pentosan polysulfate sodium (PPS) have primarily been reported following oral administration of the drug. Because PPS can also be administered subcutaneously, it is important to determine whether this route of administration may also be associated with retinal toxic effects. Objective To characterize the exposure characteristics and clinical presentation of toxic maculopathy following subcutaneous administration of PPS for the treatment of arthritis. Design, Setting, and Participants This multi-institutional, retrospective case series examined 3 cases of pentosan polysulfate maculopathy (PPM) after subcutaneous administration of PPS for the treatment of arthritis at 3 centers in Miami, Florida; Los Angeles, California; and Sydney, Australia, between September 1, 2024, and July 8, 2025. Data were analyzed from July 9, 2025, to July 18, 2025. Exposure Subcutaneous administration of PPS. Main Outcomes and Measures The primary outcome was PPM after subcutaneous PPS administration for arthritis. Changes were assessed by examining drug dosage, visual acuity, and features of multimodal retinal imaging. Results Three patients with PPS toxic maculopathy presented following treatment for osteoarthritis or inflammatory arthritis. The cumulative dose was very low in all 3 cases and ranged from 45.5 to 96 g during a span of 7 to 10 years. The multimodal features in all 3 cases were classic for PPS retinal toxic effects. Conclusions and Relevance The findings of this case series suggest that PPS retinal toxic effects can occur with subcutaneous administration alone, at much lower doses than typically occurs with oral administration, potentially due to 10-fold higher bioavailability. Early recognition of this toxic maculopathy with multimodal imaging is important to limit exposure to this drug and avoid incorrect treatments. Given progression of maculopathy even following cessation, caution is advised when using subcutaneous PPS.
{"title":"Pentosan Polysulfate Maculopathy Following Subcutaneous Injections for Arthritis","authors":"Adrian T. Fung, David Sarraf, Jose M. Carrillo, Alessandro Feo, Shahin Faghihi, Caroline M. Borie, Liam Lim, Alex P. Hunyor, Nicolas A. Yannuzzi","doi":"10.1001/jamaophthalmol.2025.5069","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2025.5069","url":null,"abstract":"Importance Retinal toxic effects due to pentosan polysulfate sodium (PPS) have primarily been reported following oral administration of the drug. Because PPS can also be administered subcutaneously, it is important to determine whether this route of administration may also be associated with retinal toxic effects. Objective To characterize the exposure characteristics and clinical presentation of toxic maculopathy following subcutaneous administration of PPS for the treatment of arthritis. Design, Setting, and Participants This multi-institutional, retrospective case series examined 3 cases of pentosan polysulfate maculopathy (PPM) after subcutaneous administration of PPS for the treatment of arthritis at 3 centers in Miami, Florida; Los Angeles, California; and Sydney, Australia, between September 1, 2024, and July 8, 2025. Data were analyzed from July 9, 2025, to July 18, 2025. Exposure Subcutaneous administration of PPS. Main Outcomes and Measures The primary outcome was PPM after subcutaneous PPS administration for arthritis. Changes were assessed by examining drug dosage, visual acuity, and features of multimodal retinal imaging. Results Three patients with PPS toxic maculopathy presented following treatment for osteoarthritis or inflammatory arthritis. The cumulative dose was very low in all 3 cases and ranged from 45.5 to 96 g during a span of 7 to 10 years. The multimodal features in all 3 cases were classic for PPS retinal toxic effects. Conclusions and Relevance The findings of this case series suggest that PPS retinal toxic effects can occur with subcutaneous administration alone, at much lower doses than typically occurs with oral administration, potentially due to 10-fold higher bioavailability. Early recognition of this toxic maculopathy with multimodal imaging is important to limit exposure to this drug and avoid incorrect treatments. Given progression of maculopathy even following cessation, caution is advised when using subcutaneous PPS.","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"170 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145718240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：